Spellberg, Brad

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,537

Necrotizing Fasciitis Caused by Community-Associated Methicillin-Resistant Staphylococcus aureus in Los Angeles

Miller, L. G., Perdreau-Remington, F., Rieg, G., Mehdi, S., Perlroth, J., Bayer, A. S., Tang, A. W., Phung, T. O., & Spellberg, B. (2005) · New England Journal of Medicine

Antimicrobial Resistance in StaphylococcusStreptococcal Infections and Treatments

Cited by 1,053

Trends in antimicrobial drug development: Implications for the future

Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases

Antibiotic Use and ResistancePharmaceutical Economics and Policy

Cited by 867

Nosocomial fungal infections: epidemiology, diagnosis, and treatment

Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 738

The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial

Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 308

The iron chelator deferasirox protects mice from mucormycosis through iron starvation

Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 308

The new antibiotic mantra-“shorter is better”.

Spellberg, B. (2016) · JAMA Internal Medicine

Antibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy

Cited by 291

Mice with Disseminated Candidiasis Die of Progressive Sepsis

Spellberg, B., Ibrahim, A. S., Edwards Jr., J. E., & Filler, S. G. (2005) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilitySepsis Diagnosis and Treatment

Cited by 230

Efficacy of the Anti‐Candida rAls3p‐N or rAls1p‐N Vaccines against Disseminated and Mucosal Candidiasis

Spellberg, B. J., Ibrahim, A. S., Avanesian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G., Yeaman, M. R., & Edwards, Jr. (2006) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 180

Progress Toward a Staphylococcus aureus Vaccine

Daum, R. S., & Spellberg, B. (2012) · Clinical Infectious Diseases

Antimicrobial Resistance in Staphylococcusvaccines and immunoinformatics approaches

Cited by 165

Duration of antibiotic therapy: shorter is better

Spellberg, B., & Rice, L. B. (2019) · Annals of Internal Medicine

Antibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy

Cited by 155

Impact of Hospital Variables on Case Mix Index as a Marker of Disease Severity

Mendez, C. M., Harrington, D. W., Christenson, P., & Spellberg, B. (2014) · Population Health Management

Healthcare Policy and ManagementMedical Coding and Health Information

Cited by 130

Candida albicans Hyr1p Confers Resistance to Neutrophil Killing and Is a Potential Vaccine Target

Luo, G., Ibrahim, A. S., Spellberg, B., Nobile, C. J., Mitchell, A. P., & Fu, Y. (2010) · The Journal of Infectious Diseases

Antifungal resistance and susceptibilityFungal and yeast genetics research

Cited by 125

Short-course antibiotic therapy-replacing constantine units with “shorter is better”.

Wald-Dickler, N., & Spellberg, B. (2019) · Clinical Infectious Diseases

Antibiotic Use and ResistanceAntibiotics Pharmacokinetics and Efficacy

Cited by 117

Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity

Ibrahim, A. S., Spellberg, B. J., Avenissian, V., Fu, Y., Filler, S. G., & Edwards, J. E. (2005) · Infection and Immunity

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 83

Transferrin iron starvation therapy for lethal bacterial and fungal infections

Lin, L., Pantapalangkoor, P., Tan, B., Bruhn, K. W., Ho, T., Nielsen, T., Skaar, E. P., Zhang, Y., Bai, R., Wang, A., et al. (2014) · Journal of Infectious Diseases

Bacterial Genetics and BiotechnologyIron Metabolism and Disorders

Cited by 68

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis

Ibrahim, A. S., Gebremariam, T., French, S. W., Edwards, J. E., & Spellberg, B. (2010) · Journal of Antimicrobial Chemotherapy

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 68

Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections

Bruhn, K. W., & Spellberg, B. (2015) · Current Opinion in Microbiology

Iron Metabolism and DisordersBacterial Genetics and Biotechnology

Cited by 48

Different tumor necrosis factor α antagonists have different effects on host susceptibility to disseminated and oropharyngeal candidiasis in mice

Park, H., Solis, N. V., Louie, J. S., Spellberg, B., Rodriguez, N., & Filler, S. G. (2014) · Virulence

Antifungal resistance and susceptibilityImmunodeficiency and Autoimmune Disorders

Cited by 11